DeMay Bio is developing a biologic drug for Rheumatoid Arthritis that leverages a natural human protein to target a novel, but validated, disease mechanism directly in the joints. The new drug is an adjunct therapy, to be used alongside a patient’s immunosuppressant regimen, to achieve better disease control, and to reduce disabling joint pain, tissue damage and mobility loss.
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com